GlassScriptPhysician profile
Hosam Hakim
NPI 1619228483
$673.89
in general payments reported to CMS, 2019-2025
20 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $130 · 2021: $57.17 · 2022: $60.68 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $89.99 · Food and Beverage: $33.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $89.99 |
| Food and Beverage | $33.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $130.00 | 2019-2020 | |
| Amgen INC. | $98.15 | 2019-2022 | |
| Janssen Biotech, INC. | $89.99 | 2025 | Rybrevant |
| Astrazeneca Pharmaceuticals LP | $36.28 | 2019 | |
| Genzyme Corporation | $35.33 | 2019-2021 | |
| Celgene Corporation | $34.91 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.44 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.03 | 2019-2020 | |
| Beigene USA, INC. | $27.76 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.75 | 2019 | |
| Jazz Pharmaceuticals INC. | $21.14 | 2019 | |
| Glaxosmithkline, LLC. | $18.04 | 2025 | Ojjaara |
| Abbvie INC. | $16.24 | 2019 | |
| Lilly USA, LLC | $16.16 | 2019 | |
| Servier Pharmaceuticals LLC | $15.50 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $13.72 | 2019 | |
| Puma Biotechnology, INC. | $12.08 | 2019 | |
| Kyowa Kirin, INC. | $11.36 | 2019 | |
| Pfizer INC. | $11.01 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hosam Hakim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.